The deal size was increased to $130M in common stock from $125M in common stock. Jefferies, JPMorgan and Guggenheim acted as joint book running managers for the offering.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROK:
- ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
- ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
- ProKidney announces $125M Class A ordinary shares offering
- ProKidney price target lowered to $6 from $15 at Jefferies
- ProKidney Progresses in Kidney Disease Treatment Trials and Regulation
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue